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Introduction
Central to the role of  platelets in hemostasis and thrombosis is the dramatic morphological transforma-
tion they undergo upon contact with subendothelial collagen to generate balloon-like as well as procoag-
ulant-spread structures (1–6). Ballooning increases the surface area for phosphatidylserine (PS) exposure, 
and together with procoagulant-spread structures, it enhances microvesiculation and amplifies thrombin 
generation by the provision of  extensive procoagulant surfaces for binding of  the prothrombinase complex. 
Computer models of  changes in cell shape based on cortical tension, water, and ion entry have shown that 
these deformations are pressure driven and can be predominantly mediated by water entry (7). According-
ly, we showed that the mechanism underlying the morphological procoagulant transformations of  activat-
ed platelets is driven by a coordinated system of  Na+, Cl–, and water entry (4), and the molecular drivers of  
salt entry are likely calcium-activated chloride channels and nonspecific cation channels (4). The molecular 
pathway for water entry required for procoagulant membrane remodeling is not clear, but water channel 
aquaporins are the most likely candidates. Of  these, aquaporin-1 (AQP1) is a family member with signif-
icant levels of  transcript expression and detection by proteomics in platelets and megakaryocytes (8–10).
The aquaporins (AQPs) are a family of  passive integral membrane proteins that, in many species, facil-
itate the highly efficient yet strictly selective passage of  water and small solutes across cell membranes (11, 
12). There are 13 mammalian AQPs, including the aquaglyceroporins, which are a subset that facilitate the 
passive transport of  glycerol and small solutes, such as urea and carbon dioxide (12, 13). The first of  the 
In response to collagen stimulation, platelets use a coordinated system of fluid entry to undergo 
membrane ballooning, procoagulant spreading, and microvesiculation. We hypothesized that 
water entry was mediated by the water channel aquaporin-1 (AQP1) and aimed to determine its 
role in the platelet procoagulant response and thrombosis. We established that human and mouse 
platelets express AQP1 and localize to internal tubular membrane structures. However, deletion 
of AQP1 had minimal effects on collagen-induced platelet granule secretion, aggregation, or 
membrane ballooning. Conversely, procoagulant spreading, microvesiculation, phosphatidylserine 
exposure, and clot formation time were significantly diminished. Furthermore, in vivo thrombus 
formation after FeCl3 injury to carotid arteries was also markedly suppressed in AQP1-null mice, 
but hemostasis after tail bleeding remained normal. The mechanism involves an AQP1-mediated 
rapid membrane stretching during procoagulant spreading but not ballooning, leading to calcium 
entry through mechanosensitive cation channels and a full procoagulant response. We conclude 
that AQP1 is a major regulator of the platelet procoagulant response, able to modulate coagulation 
after injury or pathologic stimuli without affecting other platelet functional responses or 
normal hemostasis. Clinically effective AQP1 inhibitors may therefore represent a novel class of 
antiprocoagulant antithrombotics.
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AQPs discovered was human AQP1, and it is of  the subfamily of  pure water channels (14, 15). Like other 
AQPs, it forms tetramers to function as a water pore. The aromatic/arginine selectivity filter is the narrow-
est part of  this pore; it is only 2.8-Å wide but large enough for the passage of  a single water molecule (16). 
The structure and function of  AQPs have been reviewed extensively (16, 17). The distribution of  AQPs in 
mammalian tissue is broad, with notable expression in red blood cells and the vessel wall (13). Data from 
AQP-knockout mice and from humans with loss-of-function mutations in AQPs demonstrate their role 
in epithelial fluid secretion, cell migration, and edema. This suggests that modulation of  AQP expression 
or function may have broad clinical indications, such as in the treatment of  cancer, obesity, brain injury, 
glaucoma, and intracranial hypertension (13). There is some evidence of  selectivity in AQP function; for 
example, while human and mouse AQP1 regulate cell volume and membrane dynamics in a variety of  cell 
types (18), there is no evidence that AQP4 regulates cell volume. Notably, there are no useful AQP1 inhibi-
tors, and although several putative small-molecule inhibitors have been reported (19, 20), these compounds 
lack selectivity and specificity and are largely cytotoxic (13, 21, 22). Therefore, convincing evidence for the 
role of  individual AQPs in platelet procoagulant membrane dynamics and thrombosis will require the use 
of  gene knockout models (4).
In this study, we utilized AQP1-knockout mice generated by targeted gene disruption (23) and revealed 
through dynamic high-resolution imaging that AQP1 deletion diminished procoagulant spreading, microve-
siculation, and in vivo thrombus formation, while having minimal effects on platelet secretion, aggregation, 
and normal hemostasis. AQP1 mediated these events through its facilitation in collagen-stimulated plate-
lets of  rapid membrane swelling/stretching after initial salt entry. This, in turn, promoted calcium entry via 
mechanosensitive cation channels TRPC6 and Piezo1, which is required to achieve the sustained cytosolic 
calcium required for the full platelet procoagulant response. We conclude that the water channel AQP1 is 
a suitable target for the control of  thrombotic events and, that when available, clinically safe and effective 
AQP1 inhibitors may represent a novel class of  antiprocoagulant antithrombotics for the management of  
arterial thrombotic disease, including acute coronary syndrome, coronary artery disease, and stroke.
Results
The expression and subcellular localization of  AQP1 in platelets. Data on the presence of  AQP1 in platelets are 
sparse and limited in scope by the lack of  molecular evidence (24, 25). Here, we demonstrate the expression 
of  AQP1 in mouse and human platelets by immunocytochemistry using confocal immunofluorescence 
microscopy (Figure 1, A and B) and stimulated emission depletion (STED) microscopy (Supplemental 
Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.99062DS1). The immunofluorescent signal was absent in platelets isolated from AQP1-null mice 
(Supplemental Figure 1A), validating the specificity of  the antibody. Expression of  AQP1 in human and 
mouse platelets and its absence in AQP1-null mouse platelets was further confirmed by Western blot (Fig-
ure 1C). We next sought to establish the subcellular localization of  AQP1 by immunogold staining trans-
mission electron microscopy. Figure 1, D–F, shows platelet AQP1 localized to a membrane network, likely 
to be the open canalicular system (OCS).
Deletion of  AQP1 did not diminish normal platelet secretion or aggregation. Water channels have been report-
ed to mediate the vesicular swelling that regulates content expulsion during secretion in several secretory 
cells (26, 27). There is evidence for the involvement of  AQP7 in a human platelet secretion defect (28), but 
there has not yet been a report of  how AQP1 may modulate platelet secretion or aggregation. Constitutive 
deletion in mouse of  AQP1 did not affect hematological parameters, such as white or red blood cell count 
or mean platelet or red cell volume; nor did it affect platelet levels of  key surface glycoproteins (Supplemen-
tal Figure 2). We then confirmed by electron microscopy that AQP1-null platelets showed a similar distri-
bution and number of  α and dense granules as wild-type controls (Figure 2A). Similarly, granular release 
after platelet activation via glycoprotein VI remained normal (Figure 2, B and C). Under these conditions, 
integrin αIIbβ3 activation and platelet aggregation remained unchanged in AQP1
–/– platelets by comparison 
with wild-type platelets, demonstrating that integrin inside-out signaling was intact (Figure 2C). Next, we 
studied platelet spreading on a fibrinogen-coated surface to investigate integrin outside-in signaling (Figure 
2, D and E) but did not observe a significant effect of  AQP1 deletion. Together, these data indicate that 
AQP1 is not involved in the regulation of  these platelet functions. This finding is consistent with our pro-
posed role for AQP1 primarily as a mediator of  the procoagulant membrane response, rather than platelet 
secretion or aggregation.
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Procoagulant spreading and microvesiculation, but not ballooning, is attenuated by the deletion of  AQP1. Stud-
ies of  different cell types reveal a role for AQP1 in cell migration in vitro and in vivo (29). For example, 
targeted disruption of  AQP1 reduced migration of  aortic endothelial cells and limited tumor angiogenesis 
and growth (30, 31). The underlying mechanism involved AQP support for osmotic water flow across 
the plasma membrane in cell protrusions that form during migration and in the formation of  filopodia 
and lamellipodia (29, 32). Given that our data demonstrate the localization of  AQP1 in platelets to be 
primarily on membranes structures (Figure 1D), we investigated whether AQP1 was involved in the actin 
remodeling and membrane dynamics of  the platelet procoagulant response, which amplifies coagulation 
(4) and may be dysregulated in the absence of  AQP1. To address this, we utilized high-resolution 4D live-
cell imaging in tandem with pharmacological or physiological manipulations to monitor in real time the 
procoagulant membrane dynamics of  platelets as they adhere to fibrillar collagen. Data from AQP1+/+ and 
AQP1–/– mouse platelets showed that ablation of  AQP1 did not diminish the rate or extent of  procoagulant 
membrane ballooning (Figure 3A). However, platelet procoagulant spreading and microvesiculation were 
significantly reduced (Figure 3). Water entry is therefore an integral part of  the mechanism for the platelet 
procoagulant membrane dynamics, as we had previously reported (4).
Deletion of  AQP1 results in reduced thrombus formation after carotid artery injury. Platelets are a central cell 
in the generation of  arterial thrombi; however, it was important to determine whether the diminished pro-
coagulant response associated with deletion of  AQP1 would affect in vivo thrombosis. Using constitu-
tive AQP1–/– and littermate-matched AQP1+/+ mice, we assessed thrombus formation in vivo by intravital 
microscopy of  carotid arteries after ferric chloride injury and analyzed rate of  thrombus formation, throm-
bus fragility, and embolization. Figure 4 shows a substantial suppression (by 79.3% ± 8.8%) of  thrombus 
formation in vivo in the absence of  the AQP1 gene (Figure 4, A–C). Tail bleed times, however, showed no 
difference after injury, indicating normal hemostatic function (Figure 4D). Tail bleed times are dependent 
Figure 1. Expression of the water channel aquaporin-1 in human and mouse platelets. (A and B) Representative 
images of unstimulated (A) human and (B) mouse platelets probed for F-actin (phalloidin; cyan blue) and aquaporin-1 
(AQP1) (magenta) by confocal immunofluorescence microscopy. Two and three platelets are shown in A and B, respec-
tively. (C) Representative immunoblot of human and mouse platelet lysates for AQP1 (at 28 kDa) and glycosylated 
AQP1 (at 40 kDa), with GAPDH as loading control. m_AQP1, mouse AQP1; h_AQP1, human AQP1. (C) Human adipo-
cyte and human red blood cell lysates were used as negative and positive controls, respectively. Blots show human 
(h_AQP1) and C57Bl/6 mouse platelet AQP1 (m_AQP1). Immunoblots for AQP1 in mouse platelets show absence of 
expression in AQP1–/– mice. Blots are representative of 3 independent experiments. (D) Transmission electron micros-
copy of platelets isolated from WT mice is shown. (E and F) Wild-type mouse platelets processed by the Tokuyasu 
method for immunogold labeling. AQP1 located on the membrane structures of the open canalicular structure indicat-
ed by yellow arrows in reverse contrast images. Data were from platelets obtained from 6 (A and B) or 3 independent 
experiments (C–F). Scale bar: 3 μm (A and B); 100 nm in (D–F).
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upon several hemostatic mechanisms, in addition to the procoagulant platelet response, including arterial 
and arteriolar constriction. It is possible, therefore, that the tail bleed assay misses critical features that rely 
upon a procoagulant response; however, with this caveat, there is no effect of  AQP1 gene deletion on a 
physiological hemostatic response. In vitro platelet exchange experiments showed a platelet-specific delay 
in clotting times and clot formation times in blood samples lacking AQP1 gene (Figure 4E). These data 
suggest platelet-expressed AQP1 modulates thrombosis after injury or pathologic stimuli without affecting 
normal hemostasis. We were therefore keen to elucidate the mechanism by which this water channel may 
selectively regulate platelet-driven thrombosis.
AQP1 expression mediates faster platelet swelling kinetics and enhanced cytosolic calcium responses after hypotonic 
stimulus. The speed of  cell swelling as well as the magnitude of  membrane stretch or shrinkage after tonic 
challenges can be markedly altered by the expression of  the AQPs (33–35). Here, we investigated whether 
the expression of  AQP1 facilitated osmoregulation in platelets, consistent with the function of  water chan-
nels in other cell types (34, 35). Using washed platelets from AQP1-null mice and litter-matched wild-type 
controls, we assessed the rate of  water influx after hypotonic stimulus and determined platelet swelling by 
microscopy and light transmission assays. The results shown in Figure 5, A and B, revealed that the rate and 
extent of  platelet swelling was markedly higher in platelets expressing AQP1. Alone, a 2-minute exposure 
of  platelets to 70-mOsm osmotic gradient increased AQP1+/+ and AQP1–/– platelet diameter; however, the 
extent of  swelling in AQP1+/+ platelets was greater compared with platelets lacking AQP1 (Figure 5A). Sim-
ilarly, the first-order rate constants of  platelet swelling determined by optical aggregometer were markedly 
higher in the presence of  AQP1 after a 40-mOsm osmotic gradient challenge (20.4 ± 2.7 S–1 vs. 9.6 ± 1.3 S–1). 
Figure 2. Ablation of AQP1 does not alter integrin activation or secretion in mouse platelets. (A) Transmission electron microscopy of AQP1+/+ and 
AQP1–/– mouse platelets. Representative images are shown, and granule count was determined. (B) Ablation of AQP1 had no effect on platelet-dense 
granule release. AQP1+/+ and AQP1–/– mouse platelets were stimulated with 0.5 μg/ml collagen-related peptide (CRP), and ATP secretion was assessed by 
luminometry. Representative trace and graph with levels of secretion (mean ± SEM). Blue and cyan tracings of chart show percentage aggregation and 
the simultaneous ATP release recorded in AQP1+/+ mouse platelets, respectively. Corresponding tracings for AQP1–/– platelets are shown in light and deep 
magenta. (C) Washed mouse platelets (5 × 107/ml) from AQP1+/+ or AQP1–/– mice were stimulated for 10 minutes with a range of concentrations of CRP in 
the presence of 1 mM CaCl2. Integrin αIIbβ3 activation and P selectin exposure were measured by flow cytometry. The geometric mean of the fluorescence 
intensity was determined, and data are shown as the percentage of maximal control (AQP+/+) response. Curves were fitted by F test. (D) Washed platelets 
from wild-type (AQP1+/+) or AQP1-null (AQP1–/–) mice allowed to adhere to BSA-coated (2%) or fibrinogen-coated (100 μg/ml) surfaces and stained for actin 
(FITC-phalloidin). Quantification of spreading (surface area) in box-and-whisker plots. (E) Platelets adherent to BSA were stimulated with 1 U/ml thrombin 
and spreading analyzed as in D. Statistical significance was determined by 2-way ANOVA and Bonferroni post hoc test (C) and by Wilcoxon signed-rank 
test (A, B, and E). Scale bar: 500 nm (A); 3 μm (D and E). Data were from 6 independent experiments.
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Similar elevations in the rate of  swelling was recorded with 70-mOsm (34.0 ± 6.1 S–1 vs. 15.2 ± 4.4 S–1) and 
100-mOsm (57.0 ± 2.5 S–1 vs. 32.1 ± 1.9 S–1) osmotic gradients (Figure 5B). These results indicate a role for 
AQP1 in platelet swelling and shape change after osmotic challenges (Figure 5B). In parallel experiments, 
we monitored calcium mobilization after hypotonic stimulus in platelets settled on a BSA-coated surface 
(Figure 5C) and in platelets adhering to collagen in hypotonic Tyrode supplemented with 1 mM CaCl2 (Fig-
ure 5D). Alone, a hypotonic stimulus increased the peak calcium response in both human (data not shown) 
and mouse platelets (Figure 5C) and AQP1 expression significantly increased calcium mobilization in these 
platelets whether in contact with BSA- or collagen-coated surfaces (Figure 5, C and D). Together, these data 
indicate a role for AQP1 not only in facilitating shape change and osmoregulation in platelets but also in 
enhancing the calcium signaling required for procoagulant membrane dynamics.
AQP1 is localized proximal to mechanosensitive cation channels, and its deletion or mechanosensitive cat-
ion channel blockade attenuated extracellular calcium entry and PS exposure. The mediation of  intracellular 
calcium entry by AQPs has been reported in astrocytes (33) and in a subset of  retinal glial cells (35); 
both reports implicated mechanosensitive cation (MSC) channels as part of  a molecular complex that 
integrated osmoregulation and calcium signaling (33, 35). Here, we examined the possibility that a 
similar mechanism exists in platelets. To begin with we aimed to visualize transient receptor potential 
Figure 3. Platelet procoagulant spreading and phosphatidylserine exposure but not membrane ballooning is mark-
edly diminished by AQP1 ablation. (A) Time course of membrane ballooning in platelets adherent to collagen in Tyrode 
medium containing 1 mM calcium, with 4 platelet phenotypes identified as previously reported (4–6). BNS, ballooned 
nonspread platelets; BAPS, ballooned and procoagulant-spread platelet; CSNB, conventional-spread nonballooned 
platelet; NBNS, nonballooned nonspread platelets. +, annexin V+ status; -, annexin V– status. Images show a typical field 
of view of AQP1+/+ and AQP1–/– mouse platelets adherent to collagen at the 1-hour time point, with fluorescent annexin 
V (red) superimposed with corresponding P selectin images (green) and phase-contrast images. 3D images showing 
annexin V staining. Images were obtained by spinning-disk confocal microscopy (original magnification, ×100). (B) AQP1+/+ 
and AQP1–/– platelets adhering to a collagen-coated surface were monitored for microvesicle release in real time by 
imaging-based particle counting; at the 1-hour time point, microvesicles were identified (over a 70 × 90 μm field of view 
of extended focus images), as annexin V+ particles with diameter between 100 nm and 1 μm. Data are displayed as histo-
gram and inset scatter plots. Box-and-whisker plot shows a comparison of microvesicles identified from adherent AQP1+/+ 
and AQP1–/– platelets. Data analysis was performed by Wilcoxon signed-rank test. *P < 0.05 was considered significant. 
Scale bar: 10 μm. Data were from 7 independent experiments.
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C1 (TRPC1) and C6 (TRPC6) and piezo1 in human and mouse platelets (Figure 6A). From our immu-
nocytochemistry data, we determined, as previously reported (36), the percentage of  signal colocaliza-
tion of  AQP1 versus TRPC6 and AQP1 versus piezo1; the results were comparable to but significantly 
higher than similar measures of  AQP1 and TRPC1 colocalization (Figure 6A). We then studied the 
possibility of  molecular interactions between AQP1 and MSC channel proteins by Förster resonance 
energy transfer/fluorescence lifetime imaging (FRET/FLIM), which estimates intermolecular inter-
actions within ≤10 nm. The results summarized in Figure 6B showed that the fluorescent lifetime of  
TRPC6 was significantly reduced in the presence of  AQP1. We obtained similar results in our probe for 
an interaction between the mechanosensitive channels AQP1 and Piezo1 in platelets (data not shown). 
These data suggest the likelihood of  an interaction between AQP1 and the MSC channels TRPC6 and 
piezo1, although it remains unknown from these experiments whether AQP1 directly interacts with 
MSC channels or is part of  a molecular complex for the regulation of  calcium entry in platelets.
Next, we examined the spatiotemporal changes in cytosolic calcium of washed platelets from AQP1+/+ 
and AQP1–/– mice, as they adhered to fibrillar collagen in Tyrode of physiological tonicity, supplemented with 
1 mM calcium. As previously reported (4, 5), collagen increased cytosolic calcium in these platelets (Figure 
6, C and D), due to both store release and calcium entry, since chelation of intracellular calcium by BAPTA 
or platelet preincubation with the noncompetitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase 
(SERCA) thapsigargin markedly reduced the calcium response (Figure 6, C and D). Notably, when compared 
with wild-type controls, calcium mobilization was significantly attenuated in the absence of AQP1 (Figure 
6, C and D) but not to the same degree as that observed with BAPTA (Figure 6, C and D). This suggested 
that Ca2+ release, attenuated by preincubation with thapsigargin, remained viable even after AQP1 deletion. 
Figure 4. Constitutive (whole animal) ablation of AQP1 suppresses thrombus formation in vivo and in vitro without affecting hemostasis. (A–C) Mice 
were administered DyLight 488–conjugated anti-GPIbβ antibody to label platelets. Carotid artery damage was achieved by treatment with FeCl3. Fluores-
cently labeled platelets were imaged by intravital microscopy. Images at frames indicated in A correspond to time points indicated in C. Wild-type (AQP1+/+) 
and AQP1-null (AQP1–/–) mice images show comparable growth rates and gross morphology. (B) Median fluorescence integrated density (MFID) is shown as 
interleaved box-and-whisker plots, with whiskers showing minimum to maximum values, medians, and interquartile ranges. (C) The time course of change 
in MFID (median and minimum and maximum values) for thrombus formation in AQP1+/+ and AQP1–/– mice. (D) Tail bleed times were assessed, and data 
shown are mean ± SEM of time to stop bleeding. (E) Ablation of AQP1 in platelets delayed clotting times in intrinsic pathway analyses of whole mouse 
blood coagulation. The inset shows thromboelastometry (ROTEM) data; the histogram shows clotting time (CT) and clot formation time (CFT) for freshly 
drawn, citrated whole AQP1+/+ and AQP1–/– mouse blood. Using a platelet-rich plasma (PRP) swap approach, blood is reconstituted as shown. AQP1P+/R+ indi-
cates AQP1+/+ PRP combined with AQP1+/+ red and other cells (RBC); AQP1P+/R– indicates AQP1+/+ PRP combined with AQP1–/– RBC; AQP1P–/R+ indicates AQP1–/– 
PRP combined with AQP1+/+ RBC; and AQP1P–/R– indicates AQP1–/– PRP combined with AQP1–/– RBC. Data analysis was performed by Wilcoxon signed-rank 
test. Scale bar: 2 mm. *P < 0.05 was considered significant. Data were from 8 independent experiments.
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Furthermore, the peak and the AUC of the calcium response were comparable between AQP1+/+ and AQP1–/– 
platelets once extracellular calcium was chelated with 1 mM EGTA. This indicated that extracellular calcium 
entry, but not store calcium release, were markedly reduced by AQP1 deletion (Figure 6, C and D). Given our 
previous observation that the platelet procoagulant membrane remodeling is preceded by a sustained rise in 
cytosolic calcium (4), the present data are consistent with a role for AQP1 in facilitating calcium entry.
In these experiments, we simultaneously monitored platelet spatiotemporal exposure of PS by recording 
the real-time accumulation of annexin V on platelet membranes, along with changes in cytosolic calcium. 
Figure 6, C and D shows a delay as well as significant reductions (AQP1+/+ vs. AQP1–/–: 4.3 ± 0.6 vs. 1.7 ± 
0.3) in membrane annexin V accumulation in the absence of AQP1. Our data are thus consistent with previous 
reports demonstrating the requirement of a sustained elevation in cytosolic calcium for a full procoagulant 
response in collagen-stimulated platelets (2, 37). Furthermore, in agreement with a recent report on the role of  
MSC channels in platelet calcium signaling (38), we hypothesized that calcium entry through the MSC chan-
nels TRPC6 and piezo1 may be a major contributor to the sustained elevated calcium required for the full pro-
coagulant response. Similar to effects of platelet AQP1 ablation on calcium mobilization and PS exposure, we 
recorded in collagen-stimulated AQP1+/+ platelets preincubated with the pan-MSC channel inhibitor GsMTx4 
(39), reductions in the amplitude and AUC of intracellular calcium mobilized over time (Figure 6E), the con-
comitant accumulation of annexin V (Figure 6E), and microvesiculation (Figure 6F). The effects of AQP1 
deletion on the platelet procoagulant response are therefore phenocopied by blockade of MSC channel activity.
Figure 5. Platelet aquaporin-1 mediates rapid swelling kinetics after hypotonic shock. (A) Platelets adherent to 
serum-coated dishes were challenged with a Δ-70 mOsm osmotic change, cell swelling was monitored by phase-con-
trast microscopy, and images at indicated time points are shown. The box-and-whisker plot shows AQP1+/+ and AQP1–/– 
platelet diameter after 3 minutes of hypotonic shock. The diameter versus time graph shows the time course of change 
in diameter (blue symbols indicate AQP1–/– platelets; magenta symbols indicate AQP1+/+ platelets). (B) Using an optical 
aggregometer, light transmittance was determined in platelet suspensions in modified Tyrode solutions. Baseline light 
transmittance was recorded before and after AQP1+/+ and AQP1–/– platelet suspensions were exposed to hypotonic shock 
(Δ-40, Δ-70 and Δ-100-mOsm osmotic change). Percentage light transmission values were recorded over time and plot-
ted as shown in representative graphs. The first-order rate constants of these plots were derived for the first 20 seconds 
after hypotonic shock and plotted as shown in the box-and-whisker plot. (C) Time courses of cytosolic calcium signals 
in untreated platelets adherent to bovine serum-coated surfaces and exposed to normotonic or a 70-mOsm osmotic 
gradient stimulus; here, normotonic and hypotonic Tyrode were supplemented with 1 mM calcium. Arrows in the F/F0 
graph indicate time points for induction of hypotonic stimulus. In addition, the box-and-whisker plot of peak calcium 
mobilized in platelets is shown. From left to right, representative images of AQP1+/+ and AQP1–/– platelets at basal and 
at peak cytosolic calcium signal are shown. (D) As in C, but platelets were monitored as they adhered to collagen fibers. 
The box-and-whisker plot shows peak calcium mobilized in platelets. Arrows in time-course graph indicate the time 
point of platelet adherence to collagen fiber. Data analysis was performed by Wilcoxon signed-rank test. *P < 0.05, ** P 
< 0.01 were considered significant. Scale bar: 1 μm (A and C). Data were from 4 independent experiments.
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Discussion
The ability of  platelets to support thrombin generation and localize coagulation to wound sites is hinged 
on the rapid and dramatic shape change they undergo to form ballooned membranes, procoagulant-spread 
structures, and microvesicles. Together, these are the extended surface area that externalize PS and become 
an assembly site for the binding of  coagulation factors and the amplification of  coagulation (2, 4–6, 40). In 
this study, we demonstrate an important role for the water channel AQP1 in this procoagulant remodeling. 
First, we showed that human and mouse platelets express AQP1 in a manner that indicates their local-
ization to internal membranes, likely to be the OCS. Second, our data reveal that deletion of  AQP1 does 
not affect platelet functions that are targets for current antiplatelet therapies in stroke and cardiovascular 
disease (CVD) management. In this regard, mice lacking AQP1 showed normal hemostatic responses after 
blood vessel injury, and the platelets from these mice showed no defects in aggregation or secretion from α 
or dense granules. Third, our data demonstrate that, although procoagulant membrane ballooning remains 
unaffected by AQP1 deletion, full platelet procoagulant response after pathological injury was suppressed. 
Thrombus formation after ferric chloride injury to carotid arteries was massively reduced in vivo; in addi-
tion, the ability of  platelets to procoagulant spread and microvesiculate after collagen stimulation was 
attenuated in the absence of  AQP1. Thus, data from this study demonstrate a specific role for AQP1 in the 
membrane-swelling events that control procoagulant spreading, but not ballooning.
The present study reveals that AQP1 accelerated the agonist-induced platelet membrane swelling 
and enhanced the calcium entry required for procoagulant cytoskeletal remodeling. Our EM data suggest 
Figure 6. AQP1 is localized in proximity to mechanosensitive cation channels, and its deletion or mechanosensitive cation channel blockade attenuates 
extracellular calcium entry, PS exposure, and microvesiculation. (A) Human platelets were stained with antibodies against AQP1, TRPC6, and Piezo1, and 
images were evaluated for colocalization. Pearson’s correlation analysis demonstrates AQP1 to be in proximity to TRPC6 and Piezo1 but not in significant 
proximity to TRPC1. (B) AQP1 interaction with TRPC6 in human platelets after evaluation by Förster resonance energy transfer (FRET). (C and D) Washed 
mouse platelets in modified Tyrode supplemented with 1 mM calcium were labeled with the calcium indicator Fluo-4 (green) and Alexa Fluor 568–annexin 
V (AnxV, red) and allowed to adhere to collagen-coated surfaces. (C and D) Platelets superimposed for AnxV and Fluo-4 at time points after adherence to 
collagen corresponding to the numbered arrows in the graphs below. Data are for AQP1+/+ (magenta) and AQP1–/– (blue) platelets. Box-and-whisker plots of 
peak change and area under the curve (AUC_15 min) of calcium responses in untreated platelets (NoTrm) and in platelets pretreated with the cytosolic calci-
um chelator BAPTA-AM (1 μM), extracellular calcium chelator EGTA (1 mM), and sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor thapsigargin 
(1 μM) in AQP1+/+ and AQP1–/– platelets. Similarly, the peak change and AUC of annexin V binding were quantified and shown. (E) Mouse platelets were 
preincubated with the mechanosensitive channel inhibitor Grammostola spatulata mechanotoxin 4 (GsMTx-4) or vehicle as a control; outcome is shown 
as in C and D. (F) Microvesiculation was quantified in control (untreated) and GsMTx4-treated AQP1+/+ mouse platelets. Data analysis was performed by 
Wilcoxon signed-rank test. *P < 0.05, **P < 0.01 were considered significant. Scale bar: 1 μm (A and B). Data were from 4 independent experiments.
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that AQP1 is not expressed on the plasma membrane but rather on the OCS, and superresolution imag-
es appear to confirm this by showing AQP1 as connected punctae (Supplemental Figure 1). Although 
expressed on the OCS, AQP1 can elicit the functional consequences reported in this study, because the 
intricate internal membrane system of  the OCS is contiguous with the plasma membrane and essentially 
functions as an extended plasma membrane. Platelet OCS forms multiple connections with sites on the 
platelet surface (41) and represents a membrane reservoir that can be evaginated onto the platelet sur-
face (42) but also a fusion site for secretory granules and potentially a site for expression of  functional 
membrane channels. In this way, AQP1 channels expressed on the OCS membrane system are already in 
position for water conductance.
Figure 7. Water entry via aquaporin-1 mediates a stretch-induced amplification of calcium entry and a full procoagulant response in collagen-activated 
adherent platelets. Upon contact with subendothelial collagen, platelets (A) signal via glycoprotein receptor VI to cause a rise in cytosolic calcium and the 
activation of nonspecific cation channels as well as Ca2+-activated chloride channels (CACC), resulting in an initial salt entry, which is then followed by the 
influx of water along its concentration gradient. Water channel AQP1 facilitates rapid water entry and cell swelling, leading to stretching of the plasma 
membrane, which then activates the opening of mechanosensitive cation (MSC) channels. Of these, TRPC6 of the family of transient receptor potential 
cation (TRPC) channels and Piezo1 channels are likely candidates (39) that open to allow additional influx of extracellular calcium, sustaining the rise in 
cytosolic calcium (B–D), which is critical for activation of the lipid “scramblase,” leading to PS externalization (6) (D and E and D–H). The internal hydro-
static pressure initiates membrane swelling at regions of high calpain activity (6, 56, 57). In combination with external osmotic pressure, this leads to full-
scale irreversible membrane ballooning (D–G and D and E). Ballooning is temporally correlated with the formation of the expansive procoagulant surface, 
which subsequently breaks up as a result of multiple coalescence events to form PS+ve microvesicles (4, 5, 40). (F–H) Both ballooned nonspread (BNS; F) 
and ballooned procoagulant-spread platelets (BAPS; H) increase the procoagulant area mediating the acceleration of coagulation at wound sites (4, 5, 40). 
Data from this study indicate that AQP1 has a specific role in the membrane-swelling events that control procoagulant spreading but not ballooning. Upon 
ablation of AQP1, platelet swelling kinetics are slowed and unable to or only weakly activate MSC channels for enhanced Ca2+ entry. This results in limited 
Ca2+ influx and procoagulant spreading, thus favoring the formation of the BNS platelet phenotype (D and E) and limited thrombosis.
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We have previously characterized the dynamics of  membrane ballooning (4), and we estimated that 
the rate of  membrane ballooning is unlikely to be limited by water channels only, given the narrow pore 
size and rate of  water passage through these channels (13, 17, 43). In the platelet procoagulant response, 
it is more likely that water entry is initially through water channels; however, as ballooning progresses, 
water also permeates through the lipid bilayer. AQP1 and the isoform AQP7, which we also found to be 
expressed in platelets (Supplemental Figure 3), are likely to be involved in this early phase of  water entry. 
Our data suggest a redundant role for AQP1 in procoagulant membrane ballooning, as this event proceed-
ed unabated after AQP1 deletion. A double or triple AQP-knockout model would be required to establish 
the role of  AQP in this early phase of  procoagulant membrane ballooning. Furthermore, unlike membrane 
ballooning and conventional spreading events, which were unaffected by AQP1 deletion (Figures 2 and 
3), PS exposure, procoagulant spreading, and the subsequent microvesiculation were tightly regulated by 
AQP1 alone (Figures 3 and 4). This suggests some specificity in the role of  different AQP isoforms, which 
are often coexpressed with each other in different cell types (13). Perhaps the spatial distribution of  these 
isoforms may explain their differential function.
Earlier, we reported on the pivotal role of  calcium in the platelet procoagulant response of  colla-
gen-stimulated platelets (4, 5). In this study, glycoprotein VI–induced cytosolic Ca2+ rise was sufficient 
to drive membrane ballooning in wild-type and AQP1-null platelets; however, the formation of  proco-
agulant-spread structures and microvesiculation was severely limited in platelets lacking AQP1 (Figure 
3). Under physiological conditions, it is likely that the full complement of  water channels is required to 
facilitate calcium entry and a full procoagulant response, which consists of  membrane ballooning, proco-
agulant spreading, and microvesiculation (4–6), and a lack of  AQP1 limits the extent of  this remodeling 
(Figure 7). A rise in Ca2+ in response to osmotic swelling is a well-reported observation in mammalian 
cells (44). AQP1 induced rapid swelling and a greater amplitude of  calcium influx, which could be inhib-
ited by GsMTx4 blockade of  MSC channels (Figures 5 and 6). Given that AQP1 is impermeable to ions, 
other channels must therefore mediate this swelling-induced Ca2+ entry. We speculate that the specific 
action of  AQP1 in the platelet procoagulant response is mediated via calcium-permeable stretch-activated 
channels, several of  which are expressed in platelets (39, 45–47). MSC channels have been demonstrat-
ed to bind to and functionally interact with several isoforms of  AQPs (33, 35, 48). Here, we confirmed 
the colocalization and fluorescence resonance energy transfer activity of  the AQP1 and MSC channels 
TRPC6 and piezo1 (Figure 6A), which suggest the likelihood of  their functioning in concert to regulate 
platelet response to osmotic changes and calcium entry. It is not clear how other molecular players trans-
late the differential AQP1-induced calcium signaling to regulate procoagulant response. One possibility 
is a direct interaction of  AQP1 with members of  the transmembrane protein (TMEM) family, which may 
act as calcium-dependent lipid scramblases or calcium-activated chloride channels, either of  which will 
limit procoagulant response in events of  attenuated Ca2+ entry (49, 50). Our initial investigations had 
revealed a direct interaction between AQP1 and TMEM40 (data not shown); however, this gene remains 
uncharacterized, and its molecular function is unknown. Further work beyond the scope of  the current 
study is needed to unravel the function of  this TMEM and the nature of  its interaction with AQP1.
A finding of  major clinical significance is the secretion-sparing action of  AQP1 deletion while throm-
bus formation is massively suppressed. Over 25% of  patients on antiplatelet drugs go on to suffer an isch-
emic event (51). In addition, a major clinical side effect associated with current antithrombotic regimens in 
the management of  CVD is the significant bleeding resulting from the use of  dual antiplatelet therapy, for 
example, aspirin and P2Y12 blockers usually targeting the inhibition of  platelet secretion (52). This status 
quo demonstrates a need for alternative targets for the control of  thrombotic events associated with CVD. 
Furthermore, platelets secrete a plethora of  releasates essential for the maintenance of  vascular integri-
ty and cardiovascular hemostasis (53). Consequently, new antithrombotic approaches that spare essential 
platelet secretion may attain greater clinical effectiveness and limit or eliminate the major side effects of  
current antiplatelet therapies. While there is some evidence for the involvement of  AQP-6 in human plate-
let secretion (28), the current data suggest that AQP1 may be a novel alternative antithrombotic target, 
since its deletion essentially spared platelets secretory functions and yet suppressed pathological thrombus 
formation in the same model. There are still no real AQP1 inhibitors (13, 19, 20); presently, only mercurial 
compounds target AQP1, but these are cytotoxic (13, 20). Work in this area in ongoing; thus, once identi-
fied, clinically safe and effective AQP1 inhibitors may represent a novel class of  antiplatelet drugs for the 
management of  acute coronary syndrome, coronary artery disease, and stroke.
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Conclusions. AQP1 is a major regulator of  the platelet procoagulant membrane dynamics and the pro-
thrombotic response. Suitable AQP1 inhibitors may therefore represent a novel class of  antiprocoagulant 
antithrombotics.
Methods
Materials. Collagen Reagens HORM Suspension was from Takeda. Cross-linked collagen-related peptide 
was synthesized by Richard Farndale (University of  Cambridge, Cambridge, United Kingdom). FITC–P 
selectin and PE-JON/A antibodies for flow cytometry were from Emfret Analytics. Alexa Fluor 568–con-
jugated annexin V and Fluo-4 AM were purchased from Life Technologies. Glass bottom 35-mm dishes 
(P35G-1.5-14-C) were obtained from MatTek Corporation. Rabbit polyclonal (IgG1) anti-AQP1 was from 
Alomone Lab Ltd. (catalog AQP-001) and Santa Cruz (H-55, catalog sc-20810). Ezrin/radixin/moesin 
(ERM), phospho-ERMT567/T564/T558/48G2) (catalog 3726) and phospho-PKC substrate (catalog 38938) antibod-
ies were from Cell Signaling Technologies (New England Biolabs). Far-red/infrared secondary antibodies 
(donkey anti-mouse, catalog 715-625-150; donkey anti-human, catalog 709-625-149) were from Jackson 
Immunoresearch. The following Alexa Fluor secondary antibodies were from Thermo Fisher Scientific: 
Alexa Fluor 488 (goat anti-rabbit, catalog A-11008; goat anti-mouse, catalog A-11001; donkey anti-rabbit, 
catalog A-21206; donkey anti-goat, catalog A-11055; donkey anti-mouse, catalog A-21202), Alexa Fluor 
568 (goat anti-rabbit, catalog A-11036; donkey anti-rabbit, catalog A10042; donkey anti-sheep, catalog 
A-21099; goat anti-mouse, catalog A-21134), and Alexa Fluor 647 (goat anti-mouse, catalog A-21235; 
goat anti-rabbit, catalog A27040; donkey anti-mouse, catalog A-31571; goat anti-rabbit, catalog A-21245; 
chicken anti-rabbit, catalog A-21443; chicken anti-goat, catalog A-21469). Chronolume (P/N 395) was 
from Chrono-log Corporation (Labmedics). NuPAGE SDS/PAGE sample buffer (catalog LA0041) was 
from Invitrogen. Pieizo1, TRPC1, and TRPC6 blocker, GsMTx4 (catalog 4912), was from Tocris. All other 
reagents were from Millipore unless otherwise indicated
Human platelet-rich plasma and washed platelet preparation. Blood was drawn into 4% trisodium citrate 
(1:9, v/v) and washed platelets were prepared as previously described (4, 5). Platelets were resuspended 
at 4 × 108/ml in modified HEPES-Tyrode buffer (135 mM NaCl, 3 mM KCl, 10 mM HEPES, 5 mM 
glucose, and 1 mM MgCl2.6 H2O, pH 7.3) containing 10 μmol/l indomethacin, 0.02 U/ml apyrase, and 
0.1% (w/v) D-glucose.
Animals. AQP1-knockout mice were generated by targeted gene disruption, as previously reported 
(23), and were provided for this study by Alan S. Verkman (University of  California San Francisco). 
Genotype analysis of  ear-punch DNA was done by PCR at weaning age. Wild-type littermates (AQP1+/+) 
were used as controls. Wild-type and AQP1-null (AQP1–/–) mice of  mixed gender were used for experi-
mentation at age 8–10 weeks.
Mouse washed platelet preparation. Mice (8–10 weeks, 20–25 g) were sacrificed by rising CO2 inhala-
tion, in accordance with Schedule 1 of  the Animals (Scientific Procedures) Act (1986), and blood was 
drawn from the inferior vena cava into 4% trisodium citrate (1:9, v/v). Prior to platelet preparation, full 
blood counts were conducted using a Pentra ES60 hematology analyser (Horiba Medical), and values were 
adjusted for anticoagulant volume. Washed platelets were prepared as previously described (4). Platelets 
were resuspended at 4 × 108/ml in modified HEPES-Tyrode buffer (135 mM NaCl, 3 mM KCl, 10 mM 
HEPES, 5 mM glucose, and 1 mM MgCl2.6 H2O, pH 7.3) containing 10 μmol/l indomethacin, 0.02 U/ml 
apyrase, and 0.1% (w/v) D-glucose.
Lumi-aggregometry. Aggregation and ATP secretion were measured simultaneously using a Chrono-log 
(490-4D) aggregometer and luciferin/luciferase reagent (Chronolume) at 37°C under stirring conditions. 
Washed platelets (2 × 108/ml) were preincubated with inhibitors or vehicle control (0.1% DMSO) for 10 min-
utes at 37°C, prior to agonist stimulation. ATP measurements were calibrated using a 2 nmol ATP standard.
Measurement of  platelet swelling and shape change. Platelets adherent on serum-coated dishes were 
challenged with a 70-mOsm osmotic gradient, and cell swelling and shape change was monitored by 
phase-contrast microscopy. Images were calibrated and platelet diameters were derived with the use 
of  the line tool in Volocity 6.3 software. In parallel experiments using an optical aggregometer (Chro-
no-log Corporation), platelet swelling in response to hypotonic shock was indirectly estimated by the 
changes in light transmission of  platelet suspension in modified Tyrode (300 mOsm). Briefly, 250 μl 
platelet suspension at 300 mOsm was placed in a cuvette maintained at 37°C; baseline light transmit-
tance was then recorded for 20 seconds, after which platelets were exposed to a hypotonic shock of  260, 
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230, and 200 mOsm by the addition of  an equal volume of  Tyrode solution of  appropriately lowered 
NaCl concentrations. Percentage light transmission values were recorded over time and plotted, and 
from these first-order rate constants were derived. Mean platelet volume was also determined using a 
Pentra ES60 hematology analyser (Horiba Medical).
Glutathione-S-transferase pull-down and proteomic assays. Human AQP1 glutathione-S-transferase (AQP1-
GST) recombinant protein (20 μg, LifeSpan BioSciences Inc.) or GST alone was incubated with 0.5 ml of  
Glutathione Sepharose 4B (GE Healthcare) in RIPA buffer (25 Mm HEPES, pH 7.4, 0.2 m NaCl, 2.5 mM 
MgCl2, 1% NP-40, 0.5% sodium deoxycholate, 10% glycerol, 1 mM PMSF, 25 mM sodium fluoride, 1 μM 
microcystin-LR, and complete protease inhibitor cocktail) at 4°C overnight with gentle top-over-bottom 
rotation. The sepharose beads were spun down at 500 g for 5 minutes at 4°C and washed 3 times with 1 ml 
RIPA buffer, and 30 μl AQP1-GST or GST sepharose beads alone were incubated with 250 μl human plate-
lets lysates (4 × 108 platelets/ml) in 0.5 ml RIPA buffer at 4°C overnight with gentle rotation. The sepharose 
beads were then sedimentated and washed as described above and subject to tandem mass tag proteomic 
or immunoblotting analysis.
Protein extraction and immunoblotting. Washed platelets (4 × 108/ml) stimulated as indicated were lysed 
in 4×NuPAGE sample buffer containing 0.5 M DTT. Lysates were analyzed by SDS-PAGE/Western 
blotting using Bis-Tris gels as previously described (54) and visualized by near-infrared detection (Odys-
sey CLx, LI-COR). For quantification of  immunoblotting, densitometry was performed using LI-COR 
Image Studio 5 Software.
Immunocytochemistry. Platelet suspension at 1 × 107 was dispensed onto MatTek dishes or coverslips 
precoated with BSA or agonist as indicated and allowed to adhere for 2 hours at 37°C in CO2 incubator. 
Excess platelets suspension was aspirated, and adherent platelets were fixed with 2% paraformaldehyde at 
room temperature for 10 minutes. This was followed by gentle rinses 3 times with wash buffer (modified 
Tyrode containing 0.01% saponin). Platelets were then permeabilized by a 5-minute exposure to 0.1% 
saponin in modified Tyrode and gently rinsed 3 times with wash buffer. Blocking of  nonspecific binding 
was achieved by the application of  block buffer (2% BSA in wash buffer) for 2 hours at room temperature. 
This was followed by the application of  primary antibody and overnight incubation at 4°C. Platelets were 
thereafter rinsed gently 3 times with wash buffer and incubated with suitable secondary antibody for 1 hour 
at room temperature. Finally, coverslips or dishes were rinsed 3 times, mounted with curing agent (ProLong 
Diamond), and stored protected from light at 4°C until viewed.
Flow cytometry. Integrin αIIbβ3 activation and α-granule secretion were measured using a PE-conjugat-
ed antibody (JON/A) directed against the high-affinity form of  integrin αIIbβ3 and a FITC-conjugated 
antibody (Wug.E9) for the α-granule marker CD62P (P selectin). Washed mouse platelets (1 × 106/ml 
in modified HEPES-Tyrode buffer containing 10 μmol/l indomethacin, 0.02 U/ml apyrase, 0.1% [w/v] 
D-glucose, and 1 mM CaCl2) were stimulated with agonist (10 minutes) in the presence of  FITC-JON/A 
and PE-CD62P before fixation with 1% paraformaldehyde for 30 minutes. Two-color fluorescent analysis 
was conducted on a FACSCalibur flow cytometer (BD Biosciences) using FACSDiva software. Based on 
forward and side scatter, the platelet population was gated and 20,000 events were captured.
Live platelet imaging. Platelets were preincubated (10 minutes) with probes as indicated in figures and leg-
ends. Fibrillar collagen (20 μg/ml) was used to precoat MatTek dishes and then blocked with 2% fatty acid–
free BSA. Aliquots of  washed platelets suspended in Tyrode supplemented with 1 mmol/l CaCl2 were added 
onto dishes, and platelet activities were monitored in xy or xyz dimensions over time. High-resolution 3D and 
4D images of  live-platelets adhering over agonist-coated surfaces were obtained at 25°C using spinning-disk 
confocal system as previously described (4, 5).
Image deconvolution and analysis. Image resolution was improved by the restoration complement of  
Volocity 6.3 imaging software (Perkin-Elmer). Point-spread functions specific to the microscope, refractive 
index of  immersion medium, and acquisition lens numerical aperture were calculated using the action 
menu of  the software; this was then used to conduct iterative restoration of  the fluorescent images. Using 
preinstalled Volocity algorithms, platelet-derived microvesicles were identified by intensity in 4D data using 
both Fluo-4 and annexin V signal intensities, combined with a size discrimination step for vesicles sized 
between 100 nm and 1 μm, which excluded vesicles <100 nm and >1 μm from the analysis output.
STED microscopy. Imaging was performed on a Leica STED 3× system (Leica Microsystems). Exci-
tation was provided by a white-light laser with a repetition rate of  80 MHz, and an acousto-optical 
beam splitter selected excitation wavelengths of  488 nm and 561 nm for excitation of  Alexa Fluor 488 
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and Alexa Fluor 568, respectively. Images were acquired using a 100× 1.4 NA oil immersion objective. 
Fluorescence was detected using time-gated hybrid detectors over an emission range of  492–550 nm for 
Alexa Fluor 488 detection and 568–650 nm for Alexa Fluor 568 detection. Notch filters centered on 488 
nm and 568 nm minimized any laser scatter. STED depletion was achieved through use of  592 nm (for 
Alexa Fluor 488) and 660 nm (for Alexa Fluor 568) depletion lasers.
FRET/FLIM. FLIM was used to measure changes in FRET, enabling the discrimination of  different 
states/environments of  ERM proteins in relation to AQP1 proteins. Fluorescence lifetime images were 
acquired on a Leica TCS SP8 system attached to a Leica DMi8 inverted microscope (Leica Microsys-
tems). Excitation was provided by a white-light laser, with a repetition rate of  20 MHz, and an acous-
to-optical beam splitter selected an excitation wavelength of  488 nm. Images were acquired using a 63× 
1.4 NA oil immersion objective. Fluorescence of  Alexa Fluor 488 was detected using a hybrid detector 
operating in photon-counting mode over an emission range of  495–530 nm. A notch filter centered on 
488 nm minimized any laser scatter into the detector. Time resolved data were acquired through use of  
a PicoHarp 300 TCSPC module (PicoQuant) controlled through SymPhoTime64 software (PicoQuant). 
FLIM images were acquired with 256 × 256 pixels and 4,096 time bins. Fitting of  FLIM images was 
performed with the FLIMfit software tool developed at Imperial College London (55). Temporal binning 
of  the fluorescence decays was performed prior to fitting, resulting in 256 time bins per decay. Global 
analysis fitting of  the images was then performed image wise, with a double exponential model on all 
pixels above an intensity threshold of  100 photons, allowing spatial variations in the intensity-weighted 
mean fluorescence lifetime to be visualized.
Sample processing for embedding in EPOXY resin. Platelet-rich plasma was collected and spun at 590 g 
for 5 minutes. Supernatant was removed from the platelet pellet, and the pellet was fixed in 2.5% glu-
taraldehyde in 0.1 M phosphate buffer (PB) (pH7.4). The pellet was washed in PB and then incubated 
in 1% osmium tetroxide in PB for 30 minutes. After washing in PB and deionized water, the pellet was 
incubated in 3% uranyl acetate in deionized water for 30 minutes. After washing with deionized water, 
the pellet was dehydrated in a graded series of  increasing amounts of  ethanol (70%, 80%, 90%, 96%, 
100%, and 100%, with each step lasting for 10 minutes). After removal of  the 100% ethanol, the pellet 
was incubated with pure Epon for 2 hours at room temperature. Thereafter, the Epon was replaced with 
fresh Epon, and this was hardened overnight in a 60°C oven. Subcellular morphology of  platelets in 
ultrathin counterstained sections were imaged with a Tecnai Spirit T12 microscope (FEI) and analyzed 
with Fiji software. Granule numbers were quantified manually and expressed as granules/cell/image.
Immunogold labeling of  Tokuyasu cryosection. Platelet pellets, formed by spinning platelet-rich plasma 
at 590 g for 5 minutes were fixed with 2% paraformaldehyde, 0.2 glutaraldehyde in 0.1 M PB for 1 hour 
at room temperature. Cell pellets were washed with PBS before incubation in 0.15% glycine/PBS for 
10 minutes and thereafter resuspended in warm 12% gelatin at 37°C for 10 minutes before centrifuga-
tion to reform pellets. Cell pellets were subsequently cooled on ice for 30 minutes, and 0.5-mm gelatin 
blocks were cut using a razor blade. Blocks were infused with 2.3 M sucrose at 4°C for 16 hours before 
mounting onto aluminium pins and freezing in liquid nitrogen. Ultrathin cryosections were cut using 
a EM UC6 microtome equipped with a FC6 Cryo unit (Leica Microsystems). Sections were picked up 
in a 1% methylcellulose/1.75 M sucrose solution and mounted onto carbon-coated pioloform films 
on copper mesh grids. Grids were incubated on a drop of  PBS at 37°C for 30 minutes. Grids were 
transferred between drops of  0.1% glycine/PBS and 1% BSA/PBS for 10 and 30 minutes, respectively. 
Sections were labeled with AQP1 antibody diluted in 0.1% BSA/PBS for 1 hour at room temperature 
before washing in 0.1% BSA/PBS. Grids were subsequently incubated in 10 nm Protein A Gold (Cell 
Microscopy Centre) diluted in 0.1%BSA/PBS for 20 minutes. Grids were washed in 0.1% BSA/PBS 
and distilled water to remove unbound gold before counterstaining in 0.3% uranyl acetate in 1.8% meth-
ylcellulose on ice for 5 minutes. Grids were finally air dried using the wire loop method.
Ferric chloride carotid injury model in mouse. Mice were anesthetized with ketamine 100 mg/kg (Vetalar 
V, Pfizer) and 10 mg/kg xylazine (Rompun, Bayer). Platelets were labeled by intravenous administration 
of  100 mg/kg Dylight-488–conjugated anti-GPIbβ antibody, 10 minutes prior to induction of  thrombosis. 
Right carotid arteries were exposed, and 2 × 1 mm 12% ferric chloride-soaked filter paper was placed on the 
arterial adventitia for 3 minutes. Time-lapse microscopy of  the injury site for 20 minutes was performed, 
and images were processed using ImageJ (NIH). Background fluorescence values measured upstream of  
the injury site were subtracted from thrombus-specific fluorescence, and data were expressed as integrated 
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.99062
R E S E A R C H  A R T I C L E
densities. Median integrated fluorescence density was determined as the thrombus area multiplied by the 
fluorescence intensity values above background for that area.
Tail bleeding. Experiments were conducted on 25–35 g male and female mice. Mice were anesthe-
tized (100 mg/kg ketamine and 10 mg/kg xylazine intraperitoneally), and a transverse incision was 
made with a scalpel 5 mm from the tip of  the tail. The tail was immersed in normal saline (37°C) in 
a hand-held test tube, and the time from incision to cessation of  bleeding was recorded, up to a max-
imum of  10 minutes.
Statistics. Data were analyzed using GraphPad Prism 7 and are presented as box-and-whisker plots 
showing minimum to maximum values, medians, and interquartile ranges of  data. Normality was 
assessed by the D’Agostino and Pearson omnibus as well as the Shapiro-Wilk tests. We determined sta-
tistical significance by the Friedman test, followed by the Dunn multiple comparison test or Wilcoxon 
signed-rank test. P values of  less than 0.05 were considered significant.
Study approval. Human blood was obtained from healthy drug-free volunteers, who gave full informed 
consent in accordance with the Declaration of  Helsinki, with approval from the local research ethics com-
mittee of  the University of  Bristol. Mice were bred and maintained in the University of  Bristol animal 
facility in accordance with United Kingdom Home Office regulations. All procedures were undertaken 
with United Kingdom Home Office approval in accordance with the Animals (Scientific Procedures) Act 
of  1986 (PPL30/3445).
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